Scarica l'app Stockscreener
0.00
100.00%
-8.68
Dopo l'orario di chiusura:
8.69
8.69
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Published on: 2025-08-21 00:14:22 - thegnnews.com
Sage Therapeutics Inc. Enters Reversal Setup in Weekly ChartsMarket Activity Recap & Fast Entry Momentum Trade Alerts - newsyoung.net
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Postpartum Depression Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb - Barchart.com
What is the long term forecast for Sage Therapeutics Inc. stockLong Setup & Risk Adjusted Buy and Sell Alerts - thegnnews.com
Can Sage Therapeutics Inc. be recession proofStocks with Huge Upside Movement - thegnnews.com
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Announces Second Quarter 2025 Financial Results - GlobeNewswire
MACD Cross Could Confirm Trend in Sage Therapeutics Inc.Profit Focused Stock Screener Results Released - beatles.ru
Sage Therapeutics (NASDAQ:SAGE) Rating Increased to Hold at Wall Street Zen - MarketBeat
Is it the right time to buy Sage Therapeutics Inc. stockUnlock powerful market trend analysis - Jammu Links News
How volatile is Sage Therapeutics Inc. stock compared to the marketConsistently high returns - Jammu Links News
What is the dividend policy of Sage Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
Is Sage Therapeutics Inc. a growth stock or a value stockGet alerts on high-potential stock breakouts - Jammu Links News
Why is Sage Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market shifts with expert advice - Jammu Links News
What are the latest earnings results for Sage Therapeutics Inc.Free Investment Timing Strategies - Jammu Links News
How strong is Sage Therapeutics Inc. company’s balance sheetGet daily expert analysis on top stocks - Jammu Links News
When is Sage Therapeutics Inc. stock expected to show significant growthStrongest growth potential - Jammu Links News
What institutional investors are buying Sage Therapeutics Inc. stockExtraordinary market timing - Jammu Links News
What are Sage Therapeutics Inc. company’s key revenue driversCapitalize on high-yield stock opportunities - Jammu Links News
What makes Sage Therapeutics Inc. stock price move sharplyHigh-velocity gains - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Sage (SAGE) Q2 Revenue Jumps 264% - AOL.com
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ZimVie Inc (ZIMV) - The Globe and Mail
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com Nigeria
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com Australia
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions - AInvest
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
Sage Therapeutics 2025 Q2 Earnings Significant Revenue Growth as Net Income Loss Narrows 51.7% - AInvest
Sage Therapeutics Announces Second Quarter 2025 Financial Results - BioSpace
SAGE Therapeutics earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Sage Therapeutics Announces Second Quarter 2025 Financial Results | SAGE Stock News - GuruFocus
Market reaction to Sage Therapeutics Inc.’s recent newsWeekly Stock Opportunity Radar Scanner Activated - metal.it
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Sage Therapeutics Acquisition - AInvest
Sage Therapeutics Acquisition Advances Amid Antitrust Review Expiration and Analyst Forecasts - AInvest
Cwm LLC Buys 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Published on: 2025-07-29 04:12:23 - metal.it
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
SAGE Acquisition Advances as Antitrust Waiting Period Ends - GuruFocus
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - The Manila Times
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Acquisition of Sage Therapeutics - Quiver Quantitative
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):